Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells

V. Gandhi, W. Plunkett, S. Weller, M. Du, M. Ayres, Jr Rodriguez C.O., P. Ramakrishna, G. L. Rosner, J. P. Hodge, S. O'Brien, M. J. Keating

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Purpose: A pilot protocol was designed to evaluate the efficacy of fludarabine with nelarabine (the pro-drug of arabinosylguanine [ara-G]) in patients with hematologic malignancies. The cellular pharmacokinetics was investigated to seek a relationship between response and accumulation of ara-G triphosphate (ara-GTP) in circulating leukemia cells and to evaluate biochemical modulation of cellular ara-GTP metabolism by fludarabine triphosphate. Patients and Methods: Nine of the 13 total patients had indolent leukemias, including six whose disease failed prior fludarabine therapy. Two patients had T-acute lymphoblastic leukemia, one had chronic myelogenous leukemia, and one had mycosis fungoides. Nelarabine (1.2 g/m2) was infused on days 1,3, and 5. On days 3 and 5, fludarabine (30 mg/m2) was administered 4 hours before the nelarabine infusion. Plasma and cellular pharmacokinetic measurements were conducted during the first 5 days. Results: Seven patients had a partial or complete response, six of whom had indolent leukemias. The disease in four responders had failed prior fludarabine therapy. The median peak intracellular concentrations of ara-GTP were significantly different (P = .001) in responders (890 μmol/L, n = 6) and nonresponders (30 μmol/L, n = 6). Also, there was a direct relationship between the peak fludarabine triphosphate and ara-GTP in each patient (r = 0.85). The cellular elimination of ara-GTP was slow (median, 35 hours; range, 18 to > 48 hours). The ratio of ara-GTP to its normal counterpart, deoxyguanosine triphosphate, was higher in each patient (median, 42; range, 14 to 1,092) than that of fludarabine triphosphate to its normal counterpart, deoxyadenosine triphosphate (median, 2.2; range, 0.2 to 27). Conclusion: Fludarabine plus nelarabine is an effective, well-tolerated regimen against leukemias. Clinical responses suggest the need for further exploration of nelarabine against fludarabine-refractory diseases. Determination of ara-GTP levels in the target tumor population may provide a prognostic test for the activity of nelarabine.

Original languageEnglish (US)
Pages (from-to)2142-2152
Number of pages11
JournalJournal of Clinical Oncology
Volume19
Issue number8
StatePublished - Apr 15 2001
Externally publishedYes

Fingerprint

Leukemia
Pharmacokinetics
fludarabine
triphosphoric acid
nelarabine
Mycosis Fungoides
Health Services Needs and Demand
Prodrugs
Hematologic Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9-arabinofuranosylguanine
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gandhi, V., Plunkett, W., Weller, S., Du, M., Ayres, M., Rodriguez C.O., J., ... Keating, M. J. (2001). Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. Journal of Clinical Oncology, 19(8), 2142-2152.

Evaluation of the combination of nelarabine and fludarabine in leukemias : Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. / Gandhi, V.; Plunkett, W.; Weller, S.; Du, M.; Ayres, M.; Rodriguez C.O., Jr; Ramakrishna, P.; Rosner, G. L.; Hodge, J. P.; O'Brien, S.; Keating, M. J.

In: Journal of Clinical Oncology, Vol. 19, No. 8, 15.04.2001, p. 2142-2152.

Research output: Contribution to journalArticle

Gandhi, V, Plunkett, W, Weller, S, Du, M, Ayres, M, Rodriguez C.O., J, Ramakrishna, P, Rosner, GL, Hodge, JP, O'Brien, S & Keating, MJ 2001, 'Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells', Journal of Clinical Oncology, vol. 19, no. 8, pp. 2142-2152.
Gandhi, V. ; Plunkett, W. ; Weller, S. ; Du, M. ; Ayres, M. ; Rodriguez C.O., Jr ; Ramakrishna, P. ; Rosner, G. L. ; Hodge, J. P. ; O'Brien, S. ; Keating, M. J. / Evaluation of the combination of nelarabine and fludarabine in leukemias : Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 8. pp. 2142-2152.
@article{c446a0bb11ac42248982f1375a42dcaa,
title = "Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells",
abstract = "Purpose: A pilot protocol was designed to evaluate the efficacy of fludarabine with nelarabine (the pro-drug of arabinosylguanine [ara-G]) in patients with hematologic malignancies. The cellular pharmacokinetics was investigated to seek a relationship between response and accumulation of ara-G triphosphate (ara-GTP) in circulating leukemia cells and to evaluate biochemical modulation of cellular ara-GTP metabolism by fludarabine triphosphate. Patients and Methods: Nine of the 13 total patients had indolent leukemias, including six whose disease failed prior fludarabine therapy. Two patients had T-acute lymphoblastic leukemia, one had chronic myelogenous leukemia, and one had mycosis fungoides. Nelarabine (1.2 g/m2) was infused on days 1,3, and 5. On days 3 and 5, fludarabine (30 mg/m2) was administered 4 hours before the nelarabine infusion. Plasma and cellular pharmacokinetic measurements were conducted during the first 5 days. Results: Seven patients had a partial or complete response, six of whom had indolent leukemias. The disease in four responders had failed prior fludarabine therapy. The median peak intracellular concentrations of ara-GTP were significantly different (P = .001) in responders (890 μmol/L, n = 6) and nonresponders (30 μmol/L, n = 6). Also, there was a direct relationship between the peak fludarabine triphosphate and ara-GTP in each patient (r = 0.85). The cellular elimination of ara-GTP was slow (median, 35 hours; range, 18 to > 48 hours). The ratio of ara-GTP to its normal counterpart, deoxyguanosine triphosphate, was higher in each patient (median, 42; range, 14 to 1,092) than that of fludarabine triphosphate to its normal counterpart, deoxyadenosine triphosphate (median, 2.2; range, 0.2 to 27). Conclusion: Fludarabine plus nelarabine is an effective, well-tolerated regimen against leukemias. Clinical responses suggest the need for further exploration of nelarabine against fludarabine-refractory diseases. Determination of ara-GTP levels in the target tumor population may provide a prognostic test for the activity of nelarabine.",
author = "V. Gandhi and W. Plunkett and S. Weller and M. Du and M. Ayres and {Rodriguez C.O.}, Jr and P. Ramakrishna and Rosner, {G. L.} and Hodge, {J. P.} and S. O'Brien and Keating, {M. J.}",
year = "2001",
month = "4",
day = "15",
language = "English (US)",
volume = "19",
pages = "2142--2152",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Evaluation of the combination of nelarabine and fludarabine in leukemias

T2 - Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells

AU - Gandhi, V.

AU - Plunkett, W.

AU - Weller, S.

AU - Du, M.

AU - Ayres, M.

AU - Rodriguez C.O., Jr

AU - Ramakrishna, P.

AU - Rosner, G. L.

AU - Hodge, J. P.

AU - O'Brien, S.

AU - Keating, M. J.

PY - 2001/4/15

Y1 - 2001/4/15

N2 - Purpose: A pilot protocol was designed to evaluate the efficacy of fludarabine with nelarabine (the pro-drug of arabinosylguanine [ara-G]) in patients with hematologic malignancies. The cellular pharmacokinetics was investigated to seek a relationship between response and accumulation of ara-G triphosphate (ara-GTP) in circulating leukemia cells and to evaluate biochemical modulation of cellular ara-GTP metabolism by fludarabine triphosphate. Patients and Methods: Nine of the 13 total patients had indolent leukemias, including six whose disease failed prior fludarabine therapy. Two patients had T-acute lymphoblastic leukemia, one had chronic myelogenous leukemia, and one had mycosis fungoides. Nelarabine (1.2 g/m2) was infused on days 1,3, and 5. On days 3 and 5, fludarabine (30 mg/m2) was administered 4 hours before the nelarabine infusion. Plasma and cellular pharmacokinetic measurements were conducted during the first 5 days. Results: Seven patients had a partial or complete response, six of whom had indolent leukemias. The disease in four responders had failed prior fludarabine therapy. The median peak intracellular concentrations of ara-GTP were significantly different (P = .001) in responders (890 μmol/L, n = 6) and nonresponders (30 μmol/L, n = 6). Also, there was a direct relationship between the peak fludarabine triphosphate and ara-GTP in each patient (r = 0.85). The cellular elimination of ara-GTP was slow (median, 35 hours; range, 18 to > 48 hours). The ratio of ara-GTP to its normal counterpart, deoxyguanosine triphosphate, was higher in each patient (median, 42; range, 14 to 1,092) than that of fludarabine triphosphate to its normal counterpart, deoxyadenosine triphosphate (median, 2.2; range, 0.2 to 27). Conclusion: Fludarabine plus nelarabine is an effective, well-tolerated regimen against leukemias. Clinical responses suggest the need for further exploration of nelarabine against fludarabine-refractory diseases. Determination of ara-GTP levels in the target tumor population may provide a prognostic test for the activity of nelarabine.

AB - Purpose: A pilot protocol was designed to evaluate the efficacy of fludarabine with nelarabine (the pro-drug of arabinosylguanine [ara-G]) in patients with hematologic malignancies. The cellular pharmacokinetics was investigated to seek a relationship between response and accumulation of ara-G triphosphate (ara-GTP) in circulating leukemia cells and to evaluate biochemical modulation of cellular ara-GTP metabolism by fludarabine triphosphate. Patients and Methods: Nine of the 13 total patients had indolent leukemias, including six whose disease failed prior fludarabine therapy. Two patients had T-acute lymphoblastic leukemia, one had chronic myelogenous leukemia, and one had mycosis fungoides. Nelarabine (1.2 g/m2) was infused on days 1,3, and 5. On days 3 and 5, fludarabine (30 mg/m2) was administered 4 hours before the nelarabine infusion. Plasma and cellular pharmacokinetic measurements were conducted during the first 5 days. Results: Seven patients had a partial or complete response, six of whom had indolent leukemias. The disease in four responders had failed prior fludarabine therapy. The median peak intracellular concentrations of ara-GTP were significantly different (P = .001) in responders (890 μmol/L, n = 6) and nonresponders (30 μmol/L, n = 6). Also, there was a direct relationship between the peak fludarabine triphosphate and ara-GTP in each patient (r = 0.85). The cellular elimination of ara-GTP was slow (median, 35 hours; range, 18 to > 48 hours). The ratio of ara-GTP to its normal counterpart, deoxyguanosine triphosphate, was higher in each patient (median, 42; range, 14 to 1,092) than that of fludarabine triphosphate to its normal counterpart, deoxyadenosine triphosphate (median, 2.2; range, 0.2 to 27). Conclusion: Fludarabine plus nelarabine is an effective, well-tolerated regimen against leukemias. Clinical responses suggest the need for further exploration of nelarabine against fludarabine-refractory diseases. Determination of ara-GTP levels in the target tumor population may provide a prognostic test for the activity of nelarabine.

UR - http://www.scopus.com/inward/record.url?scp=0035871440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035871440&partnerID=8YFLogxK

M3 - Article

C2 - 11304766

AN - SCOPUS:0035871440

VL - 19

SP - 2142

EP - 2152

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -